JNJ Stock Analysis

Analyzing Johnson & Johnson (JNJ): An Educational Research Review

Welcome to this detailed stock research review of Johnson & Johnson (JNJ). This article is presented as an educational guide by StockValueFinder.com to help investors understand how to evaluate a company using a disciplined, metric-driven approach. Rather than relying on sentiment or news headlines, we focus on the fundamental health of the business and the valuation of the stock.

Johnson & Johnson operates within the Healthcare sector, specifically in the Drug Manufacturers - General industry. As one of the most recognized names in global healthcare, JNJ provides a useful case study for students of value investing. In this review, we will break down the company's financial health, its efficiency in using capital, and its current valuation to see how it aligns with the strict screening criteria used by StockValueFinder.

Why the StockValueFinder Score Matters

When evaluating a stock, it is easy to get overwhelmed by the sheer volume of data available in annual reports. The StockValueFinder score is designed to simplify this process by aggregating several key financial tests into a single percentage.

For Johnson & Johnson (JNJ), the system has assigned a StockValueFinder score of 83%. This score indicates that the company passed a significant majority of the fundamental health tests. However, a high score does not automatically mean a stock is a "buy" at any price. This is why JNJ currently carries a rating of WATCHLIST.

A "Watchlist" rating typically suggests that while the underlying business quality is high (as evidenced by the 83% score), the current price or valuation may not yet align with the strict requirements for a high-conviction entry. The goal of this educational review is to show you exactly which metrics contributed to that 83% score and which metric prevented it from being higher.

EPS Strength and Consistency

The first pillar of a quality business is its ability to generate consistent earnings. Earnings Per Share (EPS) represents the portion of a company's profit allocated to each outstanding share of common stock. For an investor, consistency in EPS is often more important than a single year of explosive growth, as consistency suggests a predictable and sustainable business model.

In the StockValueFinder screen, JNJ's EPS test is marked as "Passed." While the specific historical EPS numbers were not supplied for this report, the system's "Passed" status indicates that the company's earnings history meets the minimum requirements for stability and growth trends.

To understand this conceptually, imagine two companies. Company A has EPS of $1.00, $1.10, and $1.20 over three years. Company B has EPS of $0.50, $2.00, and -$0.20 over three years. Even if Company B had a higher peak, Company A is generally considered a higher-quality business because its earnings are predictable. JNJ’s "Passed" status suggests it aligns more closely with the stability of Company A.

ROIC and Capital Efficiency

Return on Invested Capital (ROIC) is one of the most critical metrics for determining if a company is actually creating value. ROIC measures how efficiently a company uses its money (both debt and equity) to generate profits.

Johnson & Johnson reports an ROIC of 20.70%.

At StockValueFinder, we generally look for an ROIC of 10% or higher. A company that consistently generates a return above 10% on its invested capital is typically viewed as having a competitive advantage or a "moat."

To put this in perspective

For example, if a company borrows money at 5% interest but only generates a 4% ROIC, it is effectively destroying value. Conversely, JNJ’s 20.70% ROIC is well above the 10% threshold, meaning the company is highly efficient at turning its investments into profit. This is why JNJ passed the ROIC test.

Interest Coverage and Financial Safety

Financial safety is measured by a company's ability to pay the interest on its outstanding debt. This is known as the Interest Coverage Ratio. It tells us how many times over a company can pay its interest expenses using its operating income.

The StockValueFinder system marks JNJ as "Passed" for the interest coverage test. While the specific ratio number was not provided in the data set, the "Passed" status confirms the company meets the internal benchmark.

StockValueFinder generally prefers an interest coverage ratio of 6 or higher. - Healthy Range: 6x or higher. - Risky Range: 2x or lower.

For educational purposes, consider a company that earns $1 million in operating income and owes $100,000 in annual interest. Its coverage is 10x, which is very safe. If another company earns $1 million but owes $500,000 in interest, its coverage is only 2x. A small dip in earnings could leave the second company unable to pay its creditors. JNJ’s "Passed" status indicates a healthy cushion between its earnings and its interest obligations.

Debt Payback and Balance Sheet Discipline

While interest coverage tells us if a company can survive in the short term, the Debt Payback period tells us how long it would take for the company to pay off its total debt using its current annual earnings. This is a measure of long-term balance sheet discipline.

Johnson & Johnson has a debt payback period of 2.43 years.

StockValueFinder prefers a debt payback period of 3 years or less. - Attractive Range: 0 to 3 years. - Weak Range: 7 years or more.

To illustrate: a company that can pay off all its debt in 1.5 years is in a much stronger position to weather an economic downturn than a company that would take 7 years to clear its obligations. Because JNJ’s payback period of 2.43 years is under the 3-year threshold, it passed the debt payback test. This suggests the company is not over-leveraged.

P/E Ratio and Valuation Discipline

This is the section where the "quality" of a business meets the "price" of the stock. The Price-to-Earnings (P/E) ratio tells us how much the market is willing to pay for every $1 of earnings.

JNJ has a P/E ratio of 41.46.

In our valuation discipline, StockValueFinder prefers a P/E of 15 or lower. This is because paying a high multiple for a stock increases the risk that the stock price will drop if the company does not grow at an extraordinary rate.

For example, if Company X and Company Y both earn $5 per share, but Company X trades at a P/E of 8 (Price = $40) and Company Y trades at a P/E of 40 (Price = $200), Company X is significantly more "value-oriented." You are paying much less for the same amount of earnings.

Because JNJ’s P/E of 41.46 is well above the 15 threshold, it did not pass the P/E valuation test. This is the primary reason why the stock is on the "Watchlist" rather than receiving a more aggressive rating, despite its strong fundamental scores.

Moving Average Trend and Entry Timing

Fundamental analysis tells us *what* to buy, but technical trends help us understand *when* to buy. We use moving averages to identify the direction of the stock's price momentum.

JNJ currently shows a "STRONG BUY TREND" based on its moving average signal. This means the stock price is trending upward in a way that suggests positive momentum. However, it is important to remember that a trend signal is a tool for timing discipline; it is not a guarantee that the stock must continue to rise.

Regarding specific entry points

In this case, no specific entry or risk levels have been provided. In a complete trading plan, these levels serve as educational reference points to help an investor avoid "chasing" a stock that has already run up too far. Without a defined pullback zone or limit buy idea, the investor is simply observing the trend without a specific tactical entry price.

Overall Financial Strengths and Weaknesses

When we synthesize the data, a clear picture of Johnson & Johnson emerges.

**Strengths:** The company is a fundamental powerhouse. It passed the EPS strength test, the ROIC test (20.70%), the interest coverage test, and the debt payback test (2.43 years). These four "Pass" marks are why the StockValueFinder score is as high as 83%. The company is efficient with its capital, manages its debt conservatively, and generates consistent earnings.

**Weaknesses:** The primary weakness is not the business itself, but the current stock price. With a P/E ratio of 41.46, the stock is trading at a significant premium compared to the StockValueFinder preference of 15 or lower. The valuation is the only metric that failed the screen.

Risks and Limitations

Every investment carries risk. For JNJ, the primary risk identified by these metrics is "valuation risk." When a stock has a high P/E ratio, the market has already "priced in" a great deal of success. If the company's growth slows down even slightly, or if the broader healthcare sector faces headwinds, stocks with high multiples often experience the sharpest price corrections.

Additionally, while the moving average shows a "Strong Buy Trend," technical trends can reverse quickly. The absence of a defined "Risk Stop" or "Trend Risk Level" in the current data means that an investor would need to determine their own exit strategy to protect their capital.

Educational Conclusion

Analyzing Johnson & Johnson (JNJ) provides a perfect lesson in the difference between a "great company" and a "great stock price."

From a business perspective, JNJ is highly disciplined. Its 20.70% ROIC and 2.43-year debt payback period show a company that knows how to grow efficiently without endangering its balance sheet. This is why it earned an 83% score.

However, from a valuation perspective, the P/E of 41.46 suggests the stock is expensive by value-investing standards. This creates a conflict: the business is high-quality, but the price is high. This conflict is exactly why the rating is "Watchlist."

For students of the market, the lesson here is to always separate the business quality (EPS, ROIC, Debt) from the price (P/E). A great company can be a poor investment if you pay too much for it. By using a systematic screen, you can identify the strength of the business first and then wait for a valuation that provides a better margin of safety.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings